Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients

Seminars in Nephrology

Volumn 24, Issue 5, 2004, Pages 417-422

  Pozzoni, Pietro ^a   Pozzi, Marco ^a   Del Vecchio, Lucia ^a   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

anemia; cardiovascular disease; chronic kidney disease; dyslipidemia; end stage renal disease; hyperphosphatemia; inflammation; oxidative stress

Indexed keywords

ALUMINUM; CALCIUM PHOSPHATE; CALCIUM SALT; OXIDIZING AGENT; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; SEVELAMER;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DIALYSIS; DISEASE COURSE; EPIDEMIOLOGICAL DATA; GENERAL CONDITION IMPROVEMENT; HEMATOCRIT; HUMAN; HYPERPHOSPHATEMIA; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; PATIENT; PREVALENCE; PRIORITY JOURNAL; STONE FORMATION; STRESS; TREATMENT OUTCOME;

ANEMIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 5444249874     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2004.06.012     Document Type: Conference Paper

References (51)

1. US Renal Data System 2002 Annual Data Report 2002 The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. F. Locatelli, D. Marcelli, F. Conte Cardiovascular disease in chronic renal failure: The challenge continues. Registro Lombardo Dialisi e Trapianto Nephrol Dial Transplant 15 suppl 5 2000 69 80
3. R.N. Foley, P.S. Parfrey, M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 suppl 3 1998 S112 S119
4. R.N. Foley, P.S. Parfrey, J.D. Harnett Clinical and echocardiographic disease in patients starting end-stage renal disease therapy Kidney Int 47 1995 186 192
5. F. Locatelli, D. Marcelli, F. Conte Patient selection affects end-stage renal disease outcome comparisons Kidney Int 57 suppl 74 2000 S94 S99
6. F. Locatelli, T. Hannedouche, S.H. Jacobson Risk factors for cardiovascular diseases in patients starting dialysis in Northern and Southern Europe Results from the MPO study Nephrol Dial Transplant 17 2002 A11 (abstr)
7. K.J. Jager, M.P. Merkus, E.W. Boeschoten Dialysis in the Netherlands The clinical condition of new patients put into a European perspective Nephrol Dial Transplant 14 1999 2438 2444
8. F. Locatelli, F.K. Port, R.L. Pisoni Patient and treatment characteristics in the MPO study Validation against the DOPPS population Nephrol Dial Transplant 18 2003 A196 (abstr)
9. F. Locatelli, D. Marcelli, F. Conte Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease J Am Soc Nephrol 12 2001 2411 2417
10. A. Levin, C.R. Thompson, J. Ethier Left ventricular mass index increase in early renal disease Impact of decline in hemoglobin Am J Kidney Dis 34 1999 125 134
11. T. Drueke, F. Locatelli, N. Clyne Cardiovascular disease characteristics of chronic kidney disease patients enrolled in the 'Cardiovascular Risk Reduction by Early Anaemia Treatment with Epoetin Beta' (CREATE) study Nephrol Dial Transplant 18 2003 A156 (abstr)
12. B.F. Culleton, M.G. Larson, P.W. Wilson Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 1999 2214 2219
13. L.M. Ruilope, A. Salvetti, K. Jamerson Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study J Am Soc Nephrol 12 2001 218 225
14. A. Levin Anemia and left ventricular hypertrophy in chronic kidney disease populations A review of the current state of knowledge Kidney Int 61 suppl 80 2002 S35 S38
15. B.C. Astor, P. Muntner, A. Levin Association of kidney function with anemia The Third National Health and Nutrition Examination Survey (1988-1994) Arch Intern Med 162 2002 1401 1408
16. F. Locatelli, R.L. Pisoni, C. Combe Anaemia in haemodialysis patients of five European countries association with morbidity and mortality in the Dialysis Outcomes and Practices Patterns Study (DOPPS) Nephrol Dial Transplant 19 2004 121 132
17. F. Valderrabano, W.H. Horl, I.C. Macdougall PRE-dialysis survey on anaemia management Nephrol Dial Transplant 18 2003 89 8100
18. F. Locatelli, F. Conte, D. Marcelli The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity--the experience of the Lombardy Dialysis Registry Nephrol Dial Transplant 13 1998 1642 1644
19. J.Z. Ma, J. Ebben, H. Xia Haematocrit level and associated mortality in haemodialysis patients J Am Soc Nephrol 10 1999 610 619
20. H. Xia, J. Ebben, J.Z. Ma Haematocrit level and hospitalizations risks in haemodialysis patients J Am Soc Nephrol 10 1999 1309 1316
21. A.J. Collins, S. Li, W. St Peter Death, hospitalization and economic associations among incident hemodialysis patients with hematocrit values of 36-39% J Am Soc Nephrol 12 2001 2465 2473
22. D.C. Holland, M. Lam Predictors of hospitalization and death among pre-dialysis patients A retrospective cohort study Nephrol Dial Transplant 15 2000 650 658
23. J.S. Silberberg, P.E. Barre, S.S. Prichard Impact of left ventricular hypertrophy on survival in end-stage renal disease Kidney Int 36 1989 286 290
24. G.M. London, F. Fabiani, S.J. Marchais Uremic cardiomyopathy An inadequate left ventricular hypertrophy Kidney Int 31 1987 973 980
25. R.N. Foley, P.S. Parfrey, J.D. Harnett The impact of anaemia on cardiomyopathy, morbidity and mortality in end-stage renal disease Am J Kidney Dis 28 1996 53 61
26. J. Portoles, A. Torralbo, P. Martin Cardiovascular effects of recombinant human erythropoietin in predialysis patients Am J Kidney Dis 29 1997 541 548
27. T. Hayashi, A. Suzuki, T. Shoji Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure Am J Kidney Dis 35 2000 250 256
28. D.S. Silverberg, D. Wexler, M. Blum The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron Nephrol Dial Transplant 18 2003 141 146
29. R.N. Foley, P.S. Parfrey, J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 2000 1325 1335
30. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000 Am J Kidney Dis 37 suppl 1 2001 S182 S238
31. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure Nephrol Dial Transplant 19 suppl 2 2004 1 47
32. M. Tonelli, W.C. Winkelmayer, K.K. Jindal The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients Kidney Int 64 2003 295 304
33. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
34. F. Moreno, D. Sanz-Guajardo, J.M. Lopez-Gomez Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients J Am Soc Nephrol 11 2000 335 342
35. H. Furuland, T. Linde, J. Ahlmen A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients Nephrol Dial Transplant 18 2003 353 361
36. G.A. Block, T.E. Hulbert-Shearon, N.W. Levin Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients a national study Am J Kidney Dis 31 1998 607 617
37. P. Raggi, A. Boulay, S. Chasan-Taber Cardiac calcification in adult hemodialysis patients A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39 2002 695 701
38. W.G. Goodman, J. Goldin, B.D. Kuizon Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 2000 1478 1483
39. G.M. Chertow, S.K. Burke, P. Raggi Treat to Goal Working Group Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 62 2002 245 252
40. K. Katsumata, K. Kusano, M. Hirata Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats Kidney Int 64 2003 441 450
41. P. Jungers, Z.A. Massy, T.N. Khoa Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients A prospective study Nephrol Dial Transplant 12 1997 2597 2602
42. A.S. Levey, J.A. Beto, B.E. Coronado National Kidney Foundation Task Force on Cardiovascular disease Controlling the epidemic of cardiovascular disease in chronic renal disease What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 32 1998 853 906
43. C. Wanner, V. Krane, G. Ruf Die Deutsche Diabetes Dialyse Studie Investigators Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis Kidney Int 56 suppl 71 1999 S222 S226
44. A.G. Bostom, B.F. Culleton Hyperhomocysteinemia in chronic renal disease J Am Soc Nephrol 10 1999 891 900
45. P. Stenvinkel Inflammation in end-stage renal failure Could it be treated? Nephrol Dial Transplant 17 suppl 8 2002 S33 S38
46. J. Zimmermann, S. Herrlinger, A. Pruy Inflammation enhances cardiovascular risk and mortality in hemodialysis patients Kidney Int 55 1999 648 658
47. K. Iseki, M. Tozawa, S. Yoshi Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients Nephrol Dial Transplant 14 1999 1956 1960
48. J.Y. Yeun, R.A. Levine, V. Mantadilok C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients Am J Kidney Dis 35 2000 469 476
49. F. Locatelli, B. Canaud, K.U. Eckardt Oxidative stress in end-stage renal disease An emerging threat to patient outcome Nephrol Dial Transplant 18 2003 1272 1280
50. M. Boaz, Z. Matas, A. Biro Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis Kidney Int 56 1999 1078 1083
51. M. Boaz, S. Smetana, T. Weinstein Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) Randomised placebo-controlled trial Lancet 356 2000 1213 1218